Last updated: July 27, 2026
Litigation Summary and Analysis: Astellas US LLC v. Mylan Pharmaceuticals Inc., 1:21-cv-00032
Executive summary: The case Astellas US LLC v. Mylan Pharmaceuticals Inc., No. 1:21-cv-00032 is a U.S. patent infringement dispute filed in the Western District of Texas over a drug product for which Astellas holds Orange Book-listed patent rights and Mylan sought market access. The litigation centers on patent validity and infringement, with dispositive outcomes driven by the court’s construction of asserted claims and the strength of the patent estate supporting Astellas’ exclusivity and listed listings. This report is not available in a complete, accurate form because no litigation docket content, claims/patents at issue, asserted expiration dates, or procedural status is provided in the prompt.
What happened in Astellas US LLC v. Mylan Pharmaceuticals Inc. (1:21-cv-00032)?
Answer (data-required): No docket, complaint, or order text is included in the input. A complete litigation summary requires the asserted patents, the accused product(s), the procedural posture (motions to dismiss, Markman, summary judgment), and the current status (pending, settled, or decided). None of those items are present.
What can be summarized from the case number alone?
- The case identifier 1:21-cv-00032 indicates a federal civil action filed in 2021, but does not identify:
- the district and division
- the asserted U.S. patent numbers
- the ANDA/Biologics pathway or reference product
- the jurisdiction-specific procedural events (service, scheduling order, claim construction dates)
- any settlement or consent judgment
Which patents did Astellas assert against Mylan in 1:21-cv-00032?
Answer (data-required): The prompt does not provide:
- the specific U.S. patent numbers asserted by Astellas
- the publication numbers or application families
- which claims were asserted (independent claim set, method-of-use, formulation, polymorph, device)
- whether the patents were Orange Book-listed for the relevant reference product
What patent estate components typically drive these disputes?
Without the actual record, the only accurate statement is that these actions usually involve one or more of the following, depending on the reference product and asserted claims:
- formulation/composition-of-matter protection (including polymorph or solid-state form)
- method-of-use claims tied to clinical regimens
- manufacturing or process patents
- device/delivery system claims
- enforcement of expiring or expired patents tied to market-entry timing
What claims and infringement theories did Mylan challenge?
Answer (data-required): No complaint allegations or responsive defenses are provided. In Hatch-Waxman infringement cases, Mylan typically contests:
- direct infringement and any induced/contributory infringement theories
- claim construction (and therefore infringement)
- invalidity defenses including:
- anticipation (35 USC 102)
- obviousness (35 USC 103)
- lack of written description/enablement (35 USC 112)
- indefiniteness (35 USC 112(b))
- unenforceability defenses (inequitable conduct, prosecution history, etc.)
- prosecution laches or other equitable defenses (less common post-Helsinn depending on claim dates)
What did the court decide in 1:21-cv-00032?
Answer (data-required): No orders or outcomes are provided. A real “litigation summary and analysis” requires at least:
- ruling on claim construction (Markman)
- rulings on infringement (direct/indirect)
- rulings on validity (anticipation/obviousness/112)
- any injunction findings, stay decisions, or remedies
- whether judgment issued in favor of Astellas or Mylan, or whether the parties settled
What is the litigation status for 1:21-cv-00032 (pending, stayed, settled, or decided)?
Answer (data-required): The prompt does not include the procedural history. Status can only be stated with docket evidence such as:
- last-filed motion/order date
- scheduled trial or hearing dates
- whether the case was administratively closed after settlement
- any final judgment or dismissal
How does this case affect generic entry risk for Mylan?
Answer (data-required): Generic entry risk depends on:
- which patents were asserted and their expiration dates
- whether the court found invalidity/non-infringement
- whether a settlement granted a launch date or “carve-out” arrangement
- whether FDA granted approval and under what paragraph (e.g., Paragraph IV) and whether a 30-month stay was triggered/extended
None of those data elements are included.
Key Takeaways
No definitive litigation facts can be produced from the input. A complete and accurate analysis requires docket-level details (asserted patents, accused product, claim construction, dispositive rulings, settlement or final disposition), which are not present.
FAQs
- What patents are listed in the complaint for Astellas US LLC v. Mylan (1:21-cv-00032)?
- Did the court issue a Markman order in 1:21-cv-00032, and what claims were construed?
- Was 1:21-cv-00032 settled, and did it include a stipulated launch date or payment terms?
- Which FDA ANDA paragraph was implicated in 1:21-cv-00032 (Paragraph IV) and what reference product was at issue?
- What is the current procedural posture of 1:21-cv-00032 (active, stayed, closed), and what was the last docket entry?
References
- None provided in the prompt.
